CytomX Therapeutics, Inc. (CTMX) P/E Ratio History
Historical price-to-earnings valuation from 2023 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, CytomX Therapeutics, Inc. (CTMX) trades at a price-to-earnings ratio of 14.1x, with a stock price of $5.37 and trailing twelve-month earnings per share of $0.17.
The current P/E is 10% below its 5-year average of 15.7x. Over the past five years, CTMX's P/E has ranged from a low of 1.3x to a high of 84.2x, placing the current valuation at the 88th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, CTMX trades at a 40% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, CTMX trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CTMX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Drug Discovery and Antibody Platforms peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
REGNRegeneron Pharmaceuticals, Inc. | $108B | 18.8 | 2.98Best | +8% |
CTMXCytomX Therapeutics, Inc. | $430M | 14.1 | - | - |
PRTCPureTech Health plc | $405M | 8.4Lowest | - | +183%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $3.19 | $0.42 | 7.6x | -52% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $2.27 | $0.58 | 3.9x | -75% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $0.64 | $0.50 | 1.3x | -92% |
| FY2024 Q4 | $1.03 | $0.40 | 2.6x | -84% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $1.18 | $0.17 | 6.8x | -57% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $1.22 | $0.14 | 8.6x | -45% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $2.18 | $0.20 | 10.7x | -32% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $1.55 | $0.02 | 84.2x | +436% |
Average P/E for displayed period: 15.7x
See CTMX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTMX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CTMX vs AGIO
See how CTMX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CTMX stock overvalued or undervalued?
CTMX trades at 14.1x P/E, near its 5-year average of 15.7x. The 88th percentile ranking places valuation within normal historical bounds.
How does CTMX's valuation compare to peers?
CytomX Therapeutics, Inc. P/E of 14.1x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is CTMX's PEG ratio?
CTMX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2023-2025.